Need a specific person's email?
Browse Protagonist Therapeutics's employee directory (about 161 employees) and reveal verified emails free.
Protagonist Therapeutics's most common email format is F.Last@protagonist-inc.com (ex. J.Doe@protagonist-inc.com), used for 98% of protagonist-inc.com addresses. Protagonist Therapeutics uses 5 email patterns across 2 domains: protagonist-inc.com and ptgx-inc.com. Percentages are the share of addresses within each domain.
| Format | Example | Share of protagonist-inc.com |
|---|---|---|
| F.Last@protagonist-inc.comMost common | J.Doe@protagonist-inc.com | |
| First.Last@protagonist-inc.com | John.Doe@protagonist-inc.com | |
| Last@protagonist-inc.com | Doe@protagonist-inc.com |
| Format | Example | Share of ptgx-inc.com |
|---|---|---|
| F.Last@ptgx-inc.comMost common | J.Doe@ptgx-inc.com | |
| Last@ptgx-inc.com | Doe@ptgx-inc.com |
Browse Protagonist Therapeutics's employee directory (about 161 employees) and reveal verified emails free.
Biotechnology ResearchCalifornia, United States51-200 Employees
Protagonist Therapeutics is a mid-sized biotechnology research company based in Newark, California. It develops peptide-based new chemical entities using a proprietary platform, aiming to deliver potent, selective compounds with potential for oral administration. The approach combines de novo peptide design with targeted chemical modifications to improve stability and oral availability. Its work targets diseases with significant unmet medical needs and sits within the biopharmaceutical sector. Public disclosures describe clinical programs such as rusfertide for polycythemia vera and related presentations at scientific meetings. In December 2025, the company announced that 52-week results from the Phase 3 VERIFY trial of rusfertide would be presented at the ASH Annual Meeting.
Most common format
F.Last@protagonist-inc.com
Example: J.Doe@protagonist-inc.com
Free with a LeadIQ account. No credit card.
Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.